AbbVie Inc. (ABBV) stock
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$294.55−0.48 (-0.16%)
Close on Nov 16, 2026Market cap $520.50BP/E 83.2Yield 2.26%
AbbVie r&d expenses
Research and development expenses are spending on new products and technology.
AbbVie's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.71B, down 25.9% year over year. For fiscal 2025 it was $9.10B, down 28.9% from the year before. Over ten years it grew 7.8% a year on average. The highest annual figure on record is $12.79B in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.10B | -28.9% |
| FY2024 | Dec 31, 2024 | $12.79B | +66.7% |
| FY2023 | Dec 31, 2023 | $7.68B | +17.9% |
| FY2022 | Dec 31, 2022 | $6.51B | -6.0% |
| FY2021 | Dec 31, 2021 | $6.92B | +8.5% |
| FY2020 | Dec 31, 2020 | $6.38B | -0.4% |
| FY2019 | Dec 31, 2019 | $6.41B | -38.0% |
| FY2018 | Dec 31, 2018 | $10.33B | +106.3% |
| FY2017 | Dec 31, 2017 | $5.01B | +14.2% |
| FY2016 | Dec 31, 2016 | $4.39B | +2.3% |
| FY2015 | Dec 31, 2015 | $4.29B | +30.0% |
| FY2014 | Dec 31, 2014 | $3.30B | +15.5% |
| FY2013 | Dec 31, 2013 | $2.86B | +2.8% |
| FY2012 | Dec 31, 2012 | $2.78B | +6.1% |
| FY2011 | Dec 31, 2011 | $2.62B | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.34B | +10.0% |
| Q1 FY2026 | Mar 31, 2026 | $2.47B | +19.6% |
| Q4 FY2025 | Dec 31, 2025 | $2.58B | -61.9% |
| Q3 FY2025 | Sep 30, 2025 | $2.32B | +8.9% |
| Q2 FY2025 | Jun 30, 2025 | $2.13B | +9.4% |
| Q1 FY2025 | Mar 31, 2025 | $2.07B | +6.6% |
| Q4 FY2024 | Dec 31, 2024 | $6.77B | +251.5% |
| Q3 FY2024 | Sep 30, 2024 | $2.13B | +23.6% |
| Q2 FY2024 | Jun 30, 2024 | $1.95B | +12.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.94B | -15.4% |
| Q4 FY2023 | Dec 31, 2023 | $1.93B | +7.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.72B | +6.8% |
| Q2 FY2023 | Jun 30, 2023 | $1.73B | +7.7% |
| Q1 FY2023 | Mar 31, 2023 | $2.29B | +53.1% |
| Q4 FY2022 | Dec 31, 2022 | $1.79B | -2.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.61B | -2.8% |
| Q2 FY2022 | Jun 30, 2022 | $1.61B | -8.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.50B | -10.2% |
| Q4 FY2021 | Dec 31, 2021 | $1.83B | +6.7% |
| Q3 FY2021 | Sep 30, 2021 | $1.66B | -2.6% |
| Q2 FY2021 | Jun 30, 2021 | $1.77B | +11.7% |
| Q1 FY2021 | Mar 31, 2021 | $1.67B | +20.9% |
| Q4 FY2020 | Dec 31, 2020 | $1.71B | +11.0% |
| Q3 FY2020 | Sep 30, 2020 | $1.71B | -25.3% |
| Q2 FY2020 | Jun 30, 2020 | $1.58B | +22.5% |
| Q1 FY2020 | Mar 31, 2020 | $1.38B | +7.0% |
| Q4 FY2019 | Dec 31, 2019 | $1.54B | -76.3% |
| Q3 FY2019 | Sep 30, 2019 | $2.29B | +80.2% |
| Q2 FY2019 | Jun 30, 2019 | $1.29B | -2.3% |
| Q1 FY2019 | Mar 31, 2019 | $1.29B | +3.6% |
| Q4 FY2018 | Dec 31, 2018 | $6.50B | +361.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.27B | +3.3% |
| Q2 FY2018 | Jun 30, 2018 | $1.32B | +7.6% |
| Q1 FY2018 | Mar 31, 2018 | $1.24B | +8.9% |
| Q4 FY2017 | Dec 31, 2017 | $1.41B | +16.5% |
| Q3 FY2017 | Sep 30, 2017 | $1.23B | +11.0% |
| Q2 FY2017 | Jun 30, 2017 | $1.23B | – |
| Q1 FY2017 | Mar 31, 2017 | $1.14B | – |
| Q4 FY2016 | Dec 31, 2016 | $1.21B | – |
| Q3 FY2016 | Sep 30, 2016 | $1.11B | – |
See a number that looks wrong?